Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) had its price objective hoisted by investment analysts at Roth Mkm from $20.00 to $28.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock.
Several other research firms have also recently commented on CLRB. StockNews.com raised Cellectar Biosciences to a “sell” rating in a research note on Thursday, December 28th. Oppenheimer reiterated an “outperform” rating and issued a $12.00 price target (up previously from $11.00) on shares of Cellectar Biosciences in a report on Thursday.
Check Out Our Latest Stock Report on Cellectar Biosciences
Cellectar Biosciences Stock Performance
Institutional Investors Weigh In On Cellectar Biosciences
Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in Cellectar Biosciences by 174.6% during the 4th quarter. Vanguard Group Inc. now owns 482,890 shares of the biopharmaceutical company’s stock valued at $1,338,000 after buying an additional 307,006 shares in the last quarter. Coastal Bridge Advisors LLC purchased a new position in shares of Cellectar Biosciences in the 4th quarter worth $64,000. Nantahala Capital Management LLC purchased a new position in shares of Cellectar Biosciences in the 4th quarter worth $3,741,000. Citadel Advisors LLC purchased a new position in shares of Cellectar Biosciences in the 4th quarter worth $191,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Cellectar Biosciences in the 4th quarter worth $3,817,000. 16.41% of the stock is currently owned by hedge funds and other institutional investors.
About Cellectar Biosciences
Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer.
Featured Articles
- Five stocks we like better than Cellectar Biosciences
- How to buy stock: A step-by-step guide for beginnersÂ
- 3 Value Stocks Too Small For Buffett’s Portfolio
- 3 Warren Buffett Stocks to Buy Now
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.